Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)

What Was Tested

The trial (not phased) is built around GIP (Gastric Inhibitory Polypeptide).

Whether the anti-resorptive effect of GIP can be maintained if the hormone is non-continuously administrated is unclear.

It had two arms (groups): Intermittent then continious (experimental) and Continious then intermittent (experimental).

The participants that recive the intermittent administration first, followed by the continious.

The participants that recives the continious administration first, follwoed by the intermittent.

The registry classes the interventions as other.

Who Took Part

The registry lists 13 actual participants took part.

It was open to people of any sex aged from 18 years up to 40 years.

Healthy volunteers could join, not only people with the condition.

The full record lists 1 inclusion and 5 exclusion criteria; among the exclusions: BMI \>28; fractures with \< 6months; comorbidities/treatments that may influence bone metabolism or procedures - -- pregnancy.

How the Study Was Run

It was run as a randomized, crossover and open-label study.

Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In the crossover set-up each of the participants took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.

Nothing was hidden in this open-label GIP (Gastric Inhibitory Polypeptide) study: the participants and staff both knew the treatment.

It started in 2025-11-10 with completion listed for 2026-09-17.

It ran at 1 site in Denmark.

Its stated primary purpose is basic science.

What Was Measured

Researchers chose this as the main measure: Serum levels of CTX (time frame: During a three day period. With 14-28 days of washout between the two administration methods).

It also tracked 2 secondary outcomes, for example Serum levels of osteocalcin and P1NP and Serum levels of GIP.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of GIP (Gastric Inhibitory Polypeptide) in 13 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.